The PE Ratio as of November 2024 (TTM) for Prometheus Biosciences, Inc. (RXDX) is -56.47

According to Prometheus Biosciences, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -56.47. This represents a change of 160.41% compared to the average of -21.69 of the last 4 quarters.

Prometheus Biosciences, Inc. (RXDX) Historical PE Ratio (quarterly & annually)

How has RXDX PE Ratio performed in the past?

The mean historical PE Ratio of Prometheus Biosciences, Inc. over the last ten years is -16.90. The current -56.47 PE Ratio has changed 33.32% with respect to the historical average. Over the past ten years (40 quarters), RXDX's PE Ratio was at its highest in in the March 2021 quarter at -2.73. The PE Ratio was at its lowest in in the March 2023 quarter at -31.15.

Prometheus Biosciences, Inc. (RXDX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Prometheus Biosciences, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Prometheus Biosciences, Inc. (RXDX) Average PE Ratio

How has RXDX PE Ratio performed in the past?

The current PE Ratio of Prometheus Biosciences, Inc. (RXDX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Prometheus Biosciences, Inc. (RXDX) PE Ratio vs. Peers

How is RXDX’s PE Ratio compared to its peers?

Prometheus Biosciences, Inc.’s PE Ratio is less than Apellis Pharmaceuticals, Inc. (-15.24), less than Akero Therapeutics, Inc. (-9.58), less than Immunovant, Inc. (-12.18), less than Madrigal Pharmaceuticals, Inc. (-14.57), less than Roivant Sciences Ltd. (1.92), less than Krystal Biotech, Inc. (104.40), less than 89bio, Inc. (-3.25), less than Pliant Therapeutics, Inc. (-3.91), greater than Arcellx, Inc. (-120.42), less than Stoke Therapeutics, Inc. (-6.11), greater than Viking Therapeutics, Inc. (-58.83), greater than Intercept Pharmaceuticals, Inc. (-91.78), less than Terns Pharmaceuticals, Inc. (-5.12), less than Reata Pharmaceuticals, Inc. (-20.07), less than IVERIC bio, Inc. (-27.51), less than Blueprint Medicines Corporation (-46.60), less than Amylyx Pharmaceuticals, Inc. (-1.38), less than Karuna Therapeutics, Inc. (-37.08), less than Day One Biopharmaceuticals, Inc. (-15.73),

Build a custom stock screener for Prometheus Biosciences, Inc. (RXDX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Prometheus Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Prometheus Biosciences, Inc. (RXDX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Prometheus Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.